RTOG Foundation Newsletter

September 2024

info@rtog.org

In this Issue:

• Meet our 2024-2025 RTOG Foundation (RTOGF) Communications Interns
• RTOGF and NRG Oncology Research at ASTRO 2024
• New Investigator Spotlight: Dr. Sophia Kamran
• NRG2024 Recap and the Next RTOGF Investigators Meeting in Phoenix

Meet the new RTOGF Communications Interns

RTOG Foundation (RTOGF) recently selected two communications interns to help RTOGF create social media content around RTOGF clinical trials. This will be the second year RTOGF will continue their communications internship program. The internship is a 12-month position starting July 1, 2024 and will allow each intern a way to get more involved with the RTOGF organization and cancer research. Interns will be also attending virtual meetings with the RTOGF Communications Committee, attending RTOGF Board Meetings, and have the opportunity to attend an RTOGF Investigators Meeting as well as the NRG Oncology Meetings.

Learn about our interns in the article below!

• Stephanie Dudzinski, MD, PhD
• Parisa Shamsesfandabadi, MD

RTOGF and NRG Oncology Research at ASTRO 2024

RTOG Foundation and NRG Oncology have research being featured in 21 presentations occurring during the American Society for Radiation Oncology (ASTRO) Annual Meeting in Washington, D.C. from September 29 through October 2, 2024.There will be two Plenary Session presentations on the NRG-LU005 study results of concurrent chemoradiation with or without atezolizumab for limited-stage small cell lung cancer as well as NRG-HN005 interim futility results of two experimental treatment arms against a control arm for patients with p16-positive, locoregionally advanced oropharyngeal cancer. Stay tuned following the Plenary Session for press and special podcast episodes on The NRG Oncology Podcast regarding the reports results. These presentations as well as all available oral and poster presentations are available in the flyer linked below.

New Investigator Spotlight:



Sophia Kamran, MD

Sophia Kamran, MD is a Radiation Oncologist and the Director of Diversity, Equity, and Inclusion in the Department of Radiation Oncology at the Massachusetts General Hospital. She is also an Assistant Professor of Radiation Oncology at Harvard Medical School. Dr. Kamran specializes in genitourinary (GU) cancer care with additional research aims focused on translational science in diverse populations. She is a member of the NRG Oncology GU Cancer Committee and is the 2023 recipient of the NRG Oncology Health Equity Fellowship supported by RTOG Foundation. Dr. Kamran is an Associate Member of the Broad Institute of MIT and Harvard. She was the 2024 Co-Chair of the Renal and Rare Tumors Track for the ASCO Genitourinary Cancers Symposium and the Organizing Chair for the 2023 Coffey-Holden Prostate Cancer Academy Meeting. Dr. Kamran is on the National Cancer Institute (NCI) P01 Massachusetts General Hospital Internal Steering Committee, serves on the Editorial Board for Clinical Genitourinary Cancer, is a GU Associate Section Editor for Practical Radiation Oncology, and serves on the American Society for Radiation Oncology (ASTRO) Workforce Diversity Committee and American Society of Clinical Oncology (ASCO) Equity, Diversity, and Inclusion Committee.

RTOGF at NRG2024 and the Next RTOGF Investigators Meeting